Flecainide inhalation - InCarda Therapeutics

Drug Profile

Flecainide inhalation - InCarda Therapeutics

Alternative Names: InRhythm™

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator InCarda Therapeutics
  • Class Class Ic antiarrhythmics; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Paroxysmal atrial fibrillation

Most Recent Events

  • 31 Aug 2016 Phase-I clinical trials in Paroxysmal atrial fibrillation (In volunteers) in Australia (Inhalation) (ACTRN12616001156471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top